Q4 EPS Forecast for Heron Therapeutics Reduced by Analyst

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Northland Capmk cut their Q4 2024 earnings estimates for Heron Therapeutics in a report released on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the biotechnology company will post earnings per share of ($0.03) for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.08) per share.

Other equities research analysts also recently issued reports about the stock. StockNews.com upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Needham & Company LLC reduced their target price on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday.

Heron Therapeutics Trading Up 2.5 %

NASDAQ:HRTX opened at $1.24 on Friday. Heron Therapeutics has a 12 month low of $0.72 and a 12 month high of $3.93. The firm has a fifty day simple moving average of $1.84 and a 200-day simple moving average of $2.52. The company has a market capitalization of $188.07 million, a P/E ratio of -6.89 and a beta of 1.81.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same quarter last year, the business earned ($0.17) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRTX. Marshall Wace LLP increased its holdings in Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after buying an additional 1,266,697 shares in the last quarter. AQR Capital Management LLC increased its holdings in Heron Therapeutics by 1,460.9% in the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after buying an additional 568,238 shares in the last quarter. Congress Park Capital LLC increased its stake in shares of Heron Therapeutics by 25.3% during the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after purchasing an additional 399,577 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Heron Therapeutics by 369.0% during the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock worth $1,273,000 after purchasing an additional 286,160 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new position in Heron Therapeutics during the second quarter worth about $837,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.